NasdaqGS:STOKBiotechs
Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)?
Stoke Therapeutics recently reported that its Phase III EMPEROR trial of zorevunersen in Dravet syndrome exceeded its 150-patient enrollment goal, reaching 162 patients with no discontinuations so far, and outlined plans to start a rolling FDA New Drug Application in the first quarter of 2027 and complete it by the third quarter of 2027.
This smoother-than-expected enrollment, together with the clean retention profile, may strengthen confidence in the trial’s execution as the company...